Novo Nordisk's oral GLP-1 weight-loss drug, Wegovy pill, continues to outsell Eli Lilly's competing tablet, Foundayo, with around 146,000 prescriptions in the week ending May 22. However, weekly prescription growth has slowed to 2% as the market adjusts to new entrants. Wegovy pill's prescription volume is about 2.4 times that of Lilly's injectable Zepbound at a similar launch stage. Lilly's Foundayo, launched in April, recorded 16,000 prescriptions in its sixth week, but its marketing campaign is yet to start, which could change the competitive landscape.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
